{"protocolSection": {"identificationModule": {"nctId": "NCT00661362", "orgStudyIdInfo": {"id": "D1680C00006"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes", "officialTitle": "A 24-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy"}, "statusModule": {"statusVerifiedDate": "2012-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-06"}, "primaryCompletionDateStruct": {"date": "2009-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-04-17", "studyFirstSubmitQcDate": "2008-04-17", "studyFirstPostDateStruct": {"date": "2008-04-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-09-20", "resultsFirstSubmitQcDate": "2012-02-06", "resultsFirstPostDateStruct": {"date": "2012-03-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-02-06", "lastUpdatePostDateStruct": {"date": "2012-03-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"], "keywords": ["DPP-4 inhibitors", "HbA1c", "Incretins"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 570, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Metformin + Saxagliptin", "interventionNames": ["Drug: Saxagliptin", "Drug: Metformin"]}, {"label": "2", "type": "PLACEBO_COMPARATOR", "description": "Metformin + Placebo", "interventionNames": ["Drug: Placebo", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin", "description": "Oral tablet, once daily for 24 weeks", "armGroupLabels": ["1"], "otherNames": ["Onglyza"]}, {"type": "DRUG", "name": "Placebo", "description": "oral tablet, once daily for 24 weeks", "armGroupLabels": ["2"]}, {"type": "DRUG", "name": "Metformin", "description": "oral tablet, once daily for 24 weeks", "armGroupLabels": ["1", "2"], "otherNames": ["Glucophage"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)", "description": "Adjusted\\* mean change from baseline in HbA1c achieved with saxagliptin 5 mg + metformin versus placebo + metformin at week 24 (LOCF, Full Analysis set). HbA1c is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value. \\*Adjusted for baseline HbA1c.", "timeFrame": "Baseline , Week 24"}], "secondaryOutcomes": [{"measure": "Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) mmol/L", "description": "Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg + metformin versus placebo + metformin at week 24 (Last Observation Carried Out (LOCF), Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value. \\*Adjusted for baseline FPG.", "timeFrame": "Baseline , Week 24"}, {"measure": "Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) mg/dL", "description": "Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg + metformin versus placebo + metformin at week 24 (LOCF, Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value. \\*Adjusted for baseline FPG.", "timeFrame": "Baseline , Week 24"}, {"measure": "Change From Baseline in the Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During a Mixed Meal Tolerance Test (MMTT) in a Subgroup", "description": "Adjusted\\* mean change from baseline in PPG AUC achieved with saxagliptin 5 mg + metformin versus placebo + metformin at week 24 (LOCF, Full Analysis set). Trapezoidal method was used to compute AUC under the 3 hour PPG curve. The change from baseline for each subject is calculated as the week 24 value minus the baseline value. \\*Adjusted for baseline PPG AUC.", "timeFrame": "Baseline , Week 24"}, {"measure": "Change From Baseline in the Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During a Mixed Meal Tolerance Test (MMTT) in a Subgroup", "description": "Adjusted\\* mean change from baseline in PPG AUC achieved with saxagliptin 5 mg + metformin versus placebo+metformin at week 24 (LOCF, Full Analysis set). Trapezoidal method was used to compute AUC under the 3 hour PPG curve. The change from baseline for each subject is calculated as the week 24 value minus the baseline value. \\*Adjusted for baseline PPG AUC.", "timeFrame": "Baseline , Week 24"}, {"measure": "Proportion of Patients Achieving a Therapeutic Glycemic Response", "description": "Proportion of participants achieving a therapeutic glycemic response, defined as having HbA1c \\< 7.0% for saxagliptin + metformin versus placebo + metformin at week 24", "timeFrame": "Baseline , Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with Type 2 diabetes\n* Treatment with metformin at a stable dose \\>1500 mg/day\n* HbA1c \u2265 7.0% and \u226410.0%\n\nExclusion Criteria:\n\n* Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes)\n* Type 1 diabetes, history of ketoacidosis, or hyperosmolar non-ketonic koma", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Peter Ohman, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}, {"name": "Deborah Price, MSc", "affiliation": "AstraZeneca", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Research Site", "city": "Hefei", "state": "Anhui", "country": "China", "geoPoint": {"lat": 31.86389, "lon": 117.28083}}, {"facility": "Research Site", "city": "Guangzhou", "state": "Guangdong", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "Research Site", "city": "Shi Jiazhuang", "state": "Hebei", "country": "China"}, {"facility": "Research Site", "city": "Ha'er Bing", "state": "Hei Longjiang", "country": "China"}, {"facility": "Research Site", "city": "Wuhan", "state": "Hu Bei", "country": "China", "geoPoint": {"lat": 30.58333, "lon": 114.26667}}, {"facility": "Research Site", "city": "Changsha", "state": "Hunan", "country": "China", "geoPoint": {"lat": 28.19874, "lon": 112.97087}}, {"facility": "Research Site", "city": "Nanjing", "state": "Jiangsu", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Research Site", "city": "Changchun", "state": "Jilin", "country": "China", "geoPoint": {"lat": 43.88, "lon": 125.32278}}, {"facility": "Research Site", "city": "Dalian", "state": "Liaoning", "country": "China", "geoPoint": {"lat": 38.91222, "lon": 121.60222}}, {"facility": "Research Site", "city": "Shenyang", "state": "Liaoning", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Research Site", "city": "Shanghai", "state": "Shanghai", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Research Site", "city": "Chengdu", "state": "Sichuan", "country": "China", "geoPoint": {"lat": 30.66667, "lon": 104.06667}}, {"facility": "Research Site", "city": "Hangzhou", "state": "Zhejiang", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Research Site", "city": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Research Site", "city": "Chongqing", "country": "China", "geoPoint": {"lat": 29.56278, "lon": 106.55278}}, {"facility": "Research Site", "city": "Tianjin", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"facility": "Research Site", "city": "Hyderabad", "state": "Andhra Pradesh", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Research Site", "city": "Bangalore", "state": "Karnataka", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Research Site", "city": "Mangalore", "state": "Karnataka", "country": "India", "geoPoint": {"lat": 12.91723, "lon": 74.85603}}, {"facility": "Research Site", "city": "Nagpur", "state": "Maharashtra", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Research Site", "city": "Bangalore", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Research Site", "city": "Seongnam", "state": "Gyeonggi-do", "country": "Korea, Republic of", "geoPoint": {"lat": 37.43861, "lon": 127.13778}}, {"facility": "Research Site", "city": "Bucheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Research Site", "city": "Daegu", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Research Site", "city": "Goyang", "country": "Korea, Republic of", "geoPoint": {"lat": 37.65639, "lon": 126.835}}, {"facility": "Research Site", "city": "Gwangju", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Research Site", "city": "Incheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Research Site", "city": "Pusan", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Research Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Uijeongbu-si", "country": "Korea, Republic of", "geoPoint": {"lat": 37.7415, "lon": 127.0474}}]}, "referencesModule": {"references": [{"pmid": "27402391", "type": "DERIVED", "citation": "Perl S, Cook W, Wei C, Iqbal N, Hirshberg B. Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment. Diabetes Ther. 2016 Sep;7(3):527-35. doi: 10.1007/s13300-016-0184-9. Epub 2016 Jul 11."}, {"pmid": "21871686", "type": "DERIVED", "citation": "Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract. 2011 Nov;94(2):217-24. doi: 10.1016/j.diabres.2011.07.035. Epub 2011 Aug 26."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Saxagliptin 5 mg + Metformin", "description": "Saxagliptin 5 mg tablet, once daily (OD), added on to stable Metformin for 24 weeks"}, {"id": "FG001", "title": "Placebo + Metformin", "description": "Placebo tablet, OD, added on to stable Metformin for 24 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomized and treated", "numSubjects": "283"}, {"groupId": "FG001", "comment": "Randomized and treated", "numSubjects": "287"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Completed 24 Weeks of treatment", "numSubjects": "254"}, {"groupId": "FG001", "comment": "Completed 24 Weeks of treatment", "numSubjects": "247"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "40"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Incorrect enrollment", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Study specific discontinuation criteria", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "11"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Severe non-compliance to protocol", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Safety reasons", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Metformin dose haven't decreasd to 2.5 g", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Saxagliptin 5 mg + Metformin", "description": "Saxagliptin 5 mg tablet, once daily (OD), added on to stable Metformin for 24 weeks"}, {"id": "BG001", "title": "Placebo + Metformin", "description": "Placebo tablet, OD, added on to stable Metformin for 24 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "283"}, {"groupId": "BG001", "value": "287"}, {"groupId": "BG002", "value": "570"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.75", "spread": "10.42"}, {"groupId": "BG001", "value": "54.36", "spread": "10.06"}, {"groupId": "BG002", "value": "54.05", "spread": "10.24"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "147"}, {"groupId": "BG001", "value": "148"}, {"groupId": "BG002", "value": "295"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "139"}, {"groupId": "BG002", "value": "275"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)", "description": "Adjusted\\* mean change from baseline in HbA1c achieved with saxagliptin 5 mg + metformin versus placebo + metformin at week 24 (LOCF, Full Analysis set). HbA1c is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value. \\*Adjusted for baseline HbA1c.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis: change from baseline to Wk 24 LOCF for efficacy, subjects must have had a baseline and at least 1 post baseline efficacy measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent", "timeFrame": "Baseline , Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "Saxagliptin 5 mg tablet, once daily (OD), added on to stable Metformin for 24 weeks"}, {"id": "OG001", "title": "Placebo + Metformin", "description": "Placebo tablet, OD, added on to stable Metformin for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "279"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.90", "spread": "0.049"}, {"groupId": "OG001", "value": "7.94", "spread": "0.050"}]}]}, {"title": "Week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.10", "spread": "0.056"}, {"groupId": "OG001", "value": "7.55", "spread": "0.062"}]}]}, {"title": "adjusted baseline HbA1c", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.78", "spread": "0.051"}, {"groupId": "OG001", "value": "-0.37", "spread": "0.050"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.42", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.55", "ciUpperLimit": "-0.29", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.067"}]}, {"type": "SECONDARY", "title": "Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) mmol/L", "description": "Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg + metformin versus placebo + metformin at week 24 (Last Observation Carried Out (LOCF), Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value. \\*Adjusted for baseline FPG.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis: change from baseline to Wk 24 LOCF for efficacy, subjects must have had a baseline and at least 1 post baseline efficacy measurement", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline , Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "Saxagliptin 5 mg tablet, once daily (OD), added on to stable Metformin for 24 weeks"}, {"id": "OG001", "title": "Placebo + Metformin", "description": "Placebo tablet, OD, added on to stable Metformin for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "278"}, {"groupId": "OG001", "value": "281"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.57", "spread": "0.117"}, {"groupId": "OG001", "value": "8.87", "spread": "0.137"}]}]}, {"title": "Week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.61", "spread": "0.117"}, {"groupId": "OG001", "value": "8.30", "spread": "0.127"}]}]}, {"title": "Adjusted Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.14", "spread": "0.114"}, {"groupId": "OG001", "value": "-0.58", "spread": "0.111"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0002", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.85", "ciUpperLimit": "-0.26", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.149"}]}, {"type": "SECONDARY", "title": "Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) mg/dL", "description": "Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg + metformin versus placebo + metformin at week 24 (LOCF, Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value. \\*Adjusted for baseline FPG.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis: change from baseline to Wk 24 LOCF for efficacy, subjects must have had a baseline and at least 1 post baseline efficacy measurement", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline , Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "Saxagliptin 5 mg tablet, once daily (OD), added on to stable Metformin for 24 weeks"}, {"id": "OG001", "title": "Placebo + Metformin", "description": "Placebo tablet, OD, added on to stable Metformin for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "278"}, {"groupId": "OG001", "value": "281"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "154.54", "spread": "2.103"}, {"groupId": "OG001", "value": "159.73", "spread": "2.467"}]}]}, {"title": "Week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "137.15", "spread": "2.116"}, {"groupId": "OG001", "value": "149.54", "spread": "2.286"}]}]}, {"title": "Adjusted Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.52", "spread": "2.051"}, {"groupId": "OG001", "value": "-10.42", "spread": "2.004"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0002", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-10.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.37", "ciUpperLimit": "-4.83", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.684"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During a Mixed Meal Tolerance Test (MMTT) in a Subgroup", "description": "Adjusted\\* mean change from baseline in PPG AUC achieved with saxagliptin 5 mg + metformin versus placebo + metformin at week 24 (LOCF, Full Analysis set). Trapezoidal method was used to compute AUC under the 3 hour PPG curve. The change from baseline for each subject is calculated as the week 24 value minus the baseline value. \\*Adjusted for baseline PPG AUC.", "populationDescription": "MMTT was measured on a subset of patients in China cohort only at baseline and Wk 24. Randomized participants who took at least 1 dose of double-blind treatment to be included in analysis: change from baseline to Wk 24 (LOCF), must have had a baseline and a post baseline data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol*min/L", "timeFrame": "Baseline , Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "Saxagliptin 5 mg tablet, once daily (OD), added on to stable Metformin for 24 weeks"}, {"id": "OG001", "title": "Placebo + Metformin", "description": "Placebo tablet, OD, added on to stable Metformin for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2355", "spread": "45.6"}, {"groupId": "OG001", "value": "2427", "spread": "51.5"}]}]}, {"title": "Week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "2058", "spread": "44.4"}, {"groupId": "OG001", "value": "2249", "spread": "46.9"}]}]}, {"title": "Adjusted Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-315", "spread": "38.6"}, {"groupId": "OG001", "value": "-160", "spread": "39.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0052", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-155", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-264", "ciUpperLimit": "-47", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "55.0"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During a Mixed Meal Tolerance Test (MMTT) in a Subgroup", "description": "Adjusted\\* mean change from baseline in PPG AUC achieved with saxagliptin 5 mg + metformin versus placebo+metformin at week 24 (LOCF, Full Analysis set). Trapezoidal method was used to compute AUC under the 3 hour PPG curve. The change from baseline for each subject is calculated as the week 24 value minus the baseline value. \\*Adjusted for baseline PPG AUC.", "populationDescription": "MMTT was measured on a subset of patients in China cohort only at baseline and Wk 24. Randomized participants who took at least 1 dose of double-blind treatment to be included in analysis: change from baseline to Wk 24 (LOCF), must have had a baseline and a post baseline data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg*min/dL", "timeFrame": "Baseline , Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "Saxagliptin 5 mg tablet, once daily (OD), added on to stable Metformin for 24 weeks"}, {"id": "OG001", "title": "Placebo + Metformin", "description": "Placebo tablet, OD, added on to stable Metformin for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "42423", "spread": "821.9"}, {"groupId": "OG001", "value": "43719", "spread": "927.3"}]}]}, {"title": "Week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "37071", "spread": "799.4"}, {"groupId": "OG001", "value": "40521", "spread": "845.7"}]}]}, {"title": "Adjusted Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5673", "spread": "695.9"}, {"groupId": "OG001", "value": "-2871", "spread": "702.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0052", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-2802", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4753", "ciUpperLimit": "-852", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "989.8"}]}, {"type": "SECONDARY", "title": "Proportion of Patients Achieving a Therapeutic Glycemic Response", "description": "Proportion of participants achieving a therapeutic glycemic response, defined as having HbA1c \\< 7.0% for saxagliptin + metformin versus placebo + metformin at week 24", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis: change from baseline to Wk 24(LOCF) for efficacy, subjects must have had a baseline and at least 1 post baseline efficacy measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline , Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "Saxagliptin 5 mg tablet, once daily (OD), added on to stable Metformin for 24 weeks"}, {"id": "OG001", "title": "Placebo + Metformin", "description": "Placebo tablet, OD, added on to stable Metformin for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "279"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "46.5"}, {"groupId": "OG001", "value": "30.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "16.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "8.0", "ciUpperLimit": "24.0"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Saxagliptin 5 mg + Metformin", "description": "Saxagliptin 5 mg tablet, once daily (OD), added on to stable Metformin for 24 weeks", "seriousNumAffected": 8, "seriousNumAtRisk": 283, "otherNumAffected": 19, "otherNumAtRisk": 283}, {"id": "EG001", "title": "Placebo + Metformin", "description": "Placebo tablet, OD, added on to stable Metformin for 24 weeks", "seriousNumAffected": 3, "seriousNumAtRisk": 287, "otherNumAffected": 13, "otherNumAtRisk": 287}], "seriousEvents": [{"term": "Anal Abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 283}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 287}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 283}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 287}]}, {"term": "Hepatitis B", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 283}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 287}]}, {"term": "Pulmonary Tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 283}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 287}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 283}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 287}]}, {"term": "Ankle Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 283}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 287}]}, {"term": "Clavicle Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 283}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 287}]}, {"term": "Rib Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 283}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 287}]}, {"term": "Cholecystitis Acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 283}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 287}]}, {"term": "Cerebral Infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 283}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 287}]}, {"term": "Diabetic Foot", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 283}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 287}]}], "otherEvents": [{"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 283}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 287}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Principal Investigator will provide AstraZeneca as soon as possible with preliminary data and drafts of proposed publications and disclosures, whether oral or in writing, with the proposed final manuscript. AZ shall have a period of 30 days from receipt of the proposed final manuscript for any publication or other disclosure to review it and may within such time require that submission for publication or disclosure of the manuscript be delayed."}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}